TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
GLORIA Overall Survival at 18 months: |
|
Press Release2023, November 28 08:00 a.m. TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase 2023, November 24 06:00 p.m. TME Pharma launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt 2023, November 18 08:00 a.m. TME Pharma announces additional data from NOX-A12 combination regimen in brain cancer presented at SNO 2023 Annual Meeting |
EventsSNO Annual Meeting 2023
November 15 -19 | Vancouver, Canada Invest Securities Biomed Forum 2024
Aram Mangasarian 17th Annual European Life Sciences CEO Forum
Aram Mangasarian (Speaker) 5th Annual Glioblastoma Development Summit
Aram Mangasarian (Panel Speaker) |